Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study

Archives of Neurology

Volumn 53, Issue 4, 1996, Pages 353-358

  Weinshenker, Brian G ^a   Issa, Maher ^b   Baskerville, Jon ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DISABILITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FORECASTING; HUMANS; LIFE TABLES; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TIME FACTORS;

EID: 0029873865     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550040093018     Document Type: Article

References (17)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study 1: clinical course and disability. Brain. 1989;112:133-146.
2. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study 2 predictive value of the early clinical course. Brain. 1989;112:1419-1428.
3. Weinshenker BG, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study 3: multivariate analysis of predictive factors and models of outcome. Brain. 1991; 114:1045-1056.
4. Weinshenker BG, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study 4: applications to planning and interpretation of clinical therapeutic trials. Brain. 1991;114.1057-1067
5. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed up population with multiple sclerosis: implications for clinical trials. Arch Neurol. 1989,46:1107-1112.
6. The Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991,337 441-446
7. The Multiple Sclerosis Study Group Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990;27:591-605.
8. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988,2 179-183.
9. Weinshenker BG, Baskerville J, Ebers GC Meta-analysis of the placebo treated groups in clinical trials of progressive MS. Neurology. In press
10. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1994, 13:119-146.
11. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 1994,241:597-604
12. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol. 1994;36(suppl):S108-S112.
13. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, and the Canadian Cooperative Multiple Sclerosis Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial Neurology. 1990;40:971-975.
14. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 1988,45 746-748
15. Verdier-Taillefer MH, Zuber M, Lyon-Caen O, et al. Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences. Eur Neurol. 1991,31:117-119.
16. Goodkin DE Cookfair D, Wende K, et al Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology. 1992;42:859-863
17. Francis DA, Bain P, Swan AV, Hughes RAC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48:299-301